Item 1.02. Termination of a Material Definitive Agreement.
On January 27, 2023 Adaptimmune Therapeutics plc ("Adaptimmune") received notice
of termination of the Amended and Restated Research Collaboration and License
Agreement Relating to Gene Editing and HLA Engineering Technology dated January
13, 2020 between Universal Cells, Inc. ("Universal Cells") and Adaptimmune
Limited ("Agreement"). Termination of the Agreement is effective 30 days
following the receipt of notice of termination. Termination follows
Adaptimmune's decision to change the cell line being used to develop its MAGE-A4
allogeneic cell therapy due to the presence of a chromosomal abnormality in the
original cell line provided by Universal Cells under the Agreement. As a result
of termination, all licenses between the parties to the Agreement will cease and
each party is requried to return all confidential information of the other
party. A separate Collaboration and License Agreement dated January 13, 2020 for
the co-development and co-commercialisation of allogeneic T-cell therapies
remains ongoing between the parties.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits.
Exhibit No. Description of Exhibit
104 Cover Page Interactive Date File (embedded within the Inline XBRL
document)
© Edgar Online, source Glimpses